Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.

Journal Article (Journal Article)

PURPOSE: Alpha-fetoprotein (AFP) is a prognostic marker for hepatocellular carcinoma (HCC). We investigated the prognostic value of AFP levels in patients who achieved complete response (CR) to transarterial chemoembolization (TACE) for HCC. MATERIALS AND METHODS: Between 2005 and 2018, 890 patients with HCC who achieved a CR to TACE were recruited. An AFP responder was defined as a patient who showed elevated levels of AFP (>10 ng/mL) during TACE, but showed normalization or a >50% reduction in AFP levels after achieving a CR. RESULTS: Among the recruited patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection were treated. Before TACE, 305 (34.3%) patients had multiple tumors, 219 (24.6%) had a maximal tumor size >3 cm, and 22 (2.5%) had portal vein tumor thrombosis. The median AFP level after achieving a CR was 6.36 ng/mL. After a CR, 473 (53.1%) patients experienced recurrence, and 417 (46.9%) died [median progression-free survival (PFS) and overall survival (OS) of 16.3 and 62.8 months, respectively]. High AFP levels at CR (>20 ng/mL) were independently associated with a shorter PFS [hazard ratio (HR)=1.403] and OS (HR=1.284), together with tumor multiplicity at TACE (HR=1.518 and 1.666, respectively). AFP non-responders at CR (76.2%, n=359 of 471) showed a shorter PFS (median 10.5 months vs. 15.5 months, HR=1.375) and OS (median 41.4 months vs. 61.8 months, HR=1.424) than AFP responders (all p=0.001). CONCLUSION: High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds clinical implications for detailed risk stratification upon achieving a CR after TACE.

Full Text

Duke Authors

Cited Authors

  • Lee, JS; Chon, YE; Kim, BK; Park, JY; Kim, DY; Ahn, SH; Han, KH; Kang, W; Choi, MS; Gwak, GY; Paik, YH; Lee, JH; Koh, KC; Paik, SW; Kim, HY; Kim, TH; Yoo, K; Ha, Y; Kim, MN; Lee, JH; Hwang, SG; Kim, SS; Cho, HJ; Cheong, JY; Cho, SW; Park, SH; Heo, NY; Hong, YM; Yoon, KT; Cho, M; Park, JG; Kang, MK; Park, SY; Kweon, YO; Tak, WY; Jang, SY; Sinn, DH; Kim, SU; Korean TACE Study Group,

Published Date

  • January 2021

Published In

Volume / Issue

  • 62 / 1

Start / End Page

  • 12 - 20

PubMed ID

  • 33381930

Pubmed Central ID

  • PMC7820452

Electronic International Standard Serial Number (EISSN)

  • 1976-2437

Digital Object Identifier (DOI)

  • 10.3349/ymj.2021.62.1.12


  • eng

Conference Location

  • Korea (South)